Form 4: Corcept Therapeutics Director Executes Stock Option and Sells Shares

Director Daniel N. Swisher Jr. exercised stock options and sold shares of Corcept Therapeutics on December 10, 2024, according to a recent SEC filing.

Summary

• On December 10, 2024, Daniel N. Swisher Jr., a director at Corcept Therapeutics, exercised stock options to acquire 2,200 shares of common stock at a price of $12.13 per share.
• Following the exercise of the options, Mr. Swisher sold 2,200 shares of common stock at a price of $59.46 per share.
• The sale was executed under a pre-arranged 10b5-1 trading plan.
• After these transactions, Mr. Swisher directly owns 10,600 stock options.

Sentiment

Score: 5

Explanation: The document is a neutral report of insider trading activity, with no indication of positive or negative sentiment.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common for publicly traded companies. It provides transparency into the transactions of company directors and officers.

Comparison to Industry Standards

• The transactions are typical for corporate insiders who often use stock options as part of their compensation.
• The use of a 10b5-1 trading plan is a common practice to avoid accusations of insider trading, aligning with industry best practices.
• The filing is consistent with SEC regulations for reporting changes in beneficial ownership.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are routine insider activities.
• The sale of shares by a director could be perceived as a slight negative signal by some investors, but the use of a 10b5-1 plan mitigates this concern.

Key Dates

Keywords

Corcept Therapeutics, CORT, stock options, insider trading, SEC Form 4, 10b5-1 plan, director, equity securities